Pediatric Vitiligo: Therapy, Safety, and Phototherapy Protocols
Key Takeaways First-line on face/neck: calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%) as steroid-sparing agents. Backbone for generalized disease: NB-UVB […]
pediatric vitiligo
Tacrolimus 0.1% in Vitiligo: Efficacy by Anatomic Zone in Children and Adults
Key Takeaways Face/neck consistently show the best repigmentation with tacrolimus 0.1%; early perifollicular islands predict response. Acral (hands/feet) and longstanding
Tacrolimus 0.1% in Vitiligo: Efficacy by Anatomic Zone in Children and Adults
Key Takeaways Facial/neck lesions show the highest response rates to tacrolimus 0.1%, often with early perifollicular islands of repigmentation. Trunk/extremities
NB-UVB 311 nm for Vitiligo: Cohort Evidence, Protocols, Predictors, and Safety
Key Takeaways NB-UVB (311–313 nm) consistently induces clinically meaningful repigmentation across multiple cohorts; face responds best, acral sites worst. Typical regimens
Psychosocial Impact of Vitiligo: Quality of Life, Stigma, and Support Strategies
Key Takeaways Vitiligo imposes a clinically meaningful quality-of-life (QoL) burden; facial and visible-area involvement, rapid progression, and darker phototypes are
Vitiligo Epidemiology & Disease Burden: Global Prevalence, Children vs Adults, Quality of Life
Key Takeaways Global point prevalence typically falls within ~0.5–2%, with heterogeneity by region and methodology. Childhood onset is common (≈30–50%